{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:29:06Z","timestamp":1767374946937,"version":"3.41.0"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["5R01MH123479","5R01MH123479","5R01MH123479"],"award-info":[{"award-number":["5R01MH123479","5R01MH123479","5R01MH123479"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41386-025-02077-4","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T22:54:18Z","timestamp":1740696858000},"page":"1265-1274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacological reduction of reverse-translated hippocampal hyperactivity in mouse: relevance for psychosis"],"prefix":"10.1038","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1730-4927","authenticated-orcid":false,"given":"Filip P.","family":"Dybowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel S.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6366-5697","authenticated-orcid":false,"given":"Carol A.","family":"Tamminga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"2077_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-022-01904-2","volume":"12","author":"DL Spark","year":"2022","unstructured":"Spark DL, Fornito A, Langmead CJ, Stewart GD. Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics. Transl Psychiatry. 2022;12:1\u201311.","journal-title":"Transl Psychiatry"},{"key":"2077_CR2","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl J Med. 2005;353:1209\u201323.","journal-title":"N. Engl J Med"},{"key":"2077_CR3","doi-asserted-by":"publisher","first-page":"9905","DOI":"10.3390\/ijms22189905","volume":"22","author":"AL Mart\u00ednez","year":"2021","unstructured":"Mart\u00ednez AL, Brea J, Rico S, de los Frailes MT, Loza MI. Cognitive deficit in schizophrenia: from etiology to novel treatments. Int J Mol Sci. 2021;22:9905.","journal-title":"Int J Mol Sci"},{"key":"2077_CR4","first-page":"1","volume":"82","author":"L Feber","year":"2024","unstructured":"Feber L, Peter NL, Chiocchia V, Schneider-Thoma J, Siafis S, Bighelli I, et al. Antipsychotic drugs and cognitive function: a systematic review and pairwise network meta-analysis. JAMA Psychiatry. 2024;82:1\u201310.","journal-title":"JAMA Psychiatry"},{"key":"2077_CR5","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1177\/0269881119855995","volume":"33","author":"K Beck","year":"2019","unstructured":"Beck K, McCutcheon R, Stephenson L, Schilderman M, Patel N, Ramsay R, et al. Prevalence of treatment-resistant psychoses in the community: a naturalistic study. J Psychopharmacol. 2019;33:1248\u201353.","journal-title":"J Psychopharmacol"},{"key":"2077_CR6","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1017\/S0033291716002014","volume":"46","author":"J Lally","year":"2016","unstructured":"Lally J, Ajnakina O, Di Forti M, Trotta A, Demjaha A, Kolliakou A, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med. 2016;46:3231\u201340.","journal-title":"Psychol Med"},{"key":"2077_CR7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","volume":"174","author":"OD Howes","year":"2017","unstructured":"Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJM, Birnbaum ML, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. AJP. 2017;174:216\u201329.","journal-title":"AJP"},{"key":"2077_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.neuron.2012.03.023","volume":"74","author":"A Bakker","year":"2012","unstructured":"Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron. 2012;74:467\u201374.","journal-title":"Neuron"},{"key":"2077_CR9","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1212\/01.wnl.0000171450.97464.49","volume":"65","author":"BC Dickerson","year":"2005","unstructured":"Dickerson BC, Salat DH, Greve DN, Chua EF, Rand-Giovannetti E, Rentz DM, et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology. 2005;65:404\u201311.","journal-title":"Neurology"},{"key":"2077_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.486811","volume":"11","author":"D K\u00e4tzel","year":"2020","unstructured":"K\u00e4tzel D, Wolff AR, Bygrave AM, Bannerman DM. Hippocampal hyperactivity as a druggable circuit-level origin of aberrant salience in schizophrenia. Front Pharm. 2020;11:486811.","journal-title":"Front Pharm"},{"key":"2077_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-021-01683-2","volume":"12","author":"S Knight","year":"2022","unstructured":"Knight S, McCutcheon R, Dwir D, Grace AA, O\u2019Daly O, McGuire P, et al. Hippocampal circuit dysfunction in psychosis. Transl Psychiatry. 2022;12:1\u201313.","journal-title":"Transl Psychiatry"},{"key":"2077_CR12","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1176\/appi.ajp.2019.19020151","volume":"176","author":"M McHugo","year":"2019","unstructured":"McHugo M, Talati P, Armstrong K, Vandekar SN, Blackford JU, Woodward ND, et al. Hyperactivity and reduced activation of anterior hippocampus in early psychosis. AJP. 2019;176:1030\u20138.","journal-title":"AJP"},{"key":"2077_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nn.3950","volume":"18","author":"JT Paz","year":"2015","unstructured":"Paz JT, Huguenard JR. Microcircuits and their interactions in epilepsy: is the focus out of focus? Nat Neurosci. 2015;18:351\u20139.","journal-title":"Nat Neurosci"},{"key":"2077_CR14","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/ana.22105","volume":"68","author":"YT Quiroz","year":"2010","unstructured":"Quiroz YT, Budson AE, Celone K, Ruiz A, Newmark R, Castrill\u00f3n G, et al. Hippocampal hyperactivation in presymptomatic familial Alzheimer\u2019s disease. Ann Neurol. 2010;68:865\u201375.","journal-title":"Ann Neurol"},{"key":"2077_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.nicl.2014.07.004","volume":"5","author":"P Talati","year":"2014","unstructured":"Talati P, Rane S, Kose S, Blackford JU, Gore J, Donahue MJ, et al. Increased hippocampal CA1 cerebral blood volume in schizophrenia. NeuroImage: Clin. 2014;5:359\u201364.","journal-title":"NeuroImage: Clin"},{"key":"2077_CR16","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1176\/appi.ajp.2013.13070981","volume":"171","author":"JR Tregellas","year":"2014","unstructured":"Tregellas JR, Smucny J, Harris JG, Olincy A, Maharajh K, Kronberg E, et al. Intrinsic hippocampal activity as a biomarker for cognition and symptoms in schizophrenia. Am J Psychiatry. 2014;171:549\u201356.","journal-title":"Am J Psychiatry"},{"key":"2077_CR17","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1176\/appi.ajp.2015.15040485","volume":"173","author":"P Allen","year":"2016","unstructured":"Allen P, Chaddock CA, Egerton A, Howes OD, Bonoldi I, Zelaya F, et al. Resting hyperperfusion of the hippocampus, midbrain, and basal ganglia in people at high risk for psychosis. Am J Psychiatry. 2016;173:392\u20139.","journal-title":"Am J Psychiatry"},{"key":"2077_CR18","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1038\/mp.2017.249","volume":"23","author":"JA Lieberman","year":"2018","unstructured":"Lieberman JA, Girgis RR, Brucato G, Moore H, Provenzano F, Kegeles L, et al. Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention. Mol Psychiatry. 2018;23:1764\u201372.","journal-title":"Mol Psychiatry"},{"key":"2077_CR19","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.schres.2022.02.003","volume":"241","author":"M McHugo","year":"2022","unstructured":"McHugo M, Rogers BP, Avery SN, Armstrong K, Blackford JU, Vandekar SN, et al. Increased amplitude of hippocampal low frequency fluctuations in early psychosis: a two-year follow-up study. Schizophrenia Res. 2022;241:260\u20136.","journal-title":"Schizophrenia Res"},{"key":"2077_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.biopsych.2019.09.022","volume":"87","author":"FA Provenzano","year":"2020","unstructured":"Provenzano FA, Guo J, Wall MM, Feng X, Sigmon HC, Brucato G, et al. Hippocampal pathology in clinical high-risk patients and the onset of schizophrenia. Biol Psychiatry. 2020;87:234\u201342.","journal-title":"Biol Psychiatry"},{"key":"2077_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.neuron.2013.02.011","volume":"78","author":"SA Schobel","year":"2013","unstructured":"Schobel SA, Chaudhury NH, Khan UA, Paniagua B, Styner MA, Asllani I, et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron. 2013;78:81\u201393.","journal-title":"Neuron"},{"key":"2077_CR22","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1001\/archgenpsychiatry.2009.115","volume":"66","author":"SA Schobel","year":"2009","unstructured":"Schobel SA, Lewandowski NM, Corcoran CM, Moore H, Brown T, Malaspina D, et al. Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch Gen Psychiatry. 2009;66:938\u201346.","journal-title":"Arch Gen Psychiatry"},{"key":"2077_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-018-0268-6","volume":"8","author":"CM Grimm","year":"2018","unstructured":"Grimm CM, Aksamaz S, Schulz S, Teutsch J, Sicinski P, Liss B, et al. Schizophrenia-related cognitive dysfunction in the Cyclin-D2 knockout mouse model of ventral hippocampal hyperactivity. Transl Psychiatry. 2018;8:212.","journal-title":"Transl Psychiatry"},{"key":"2077_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/schbul\/sby011","volume":"45","author":"SS Lander","year":"2019","unstructured":"Lander SS, Khan U, Lewandowski N, Chakraborty D, Provenzano FA, Mingote S, et al. Glutamate dehydrogenase-deficient mice display schizophrenia-like behavioral abnormalities and CA1-specific hippocampal dysfunction. Schizophr Bull. 2019;45:127\u201337.","journal-title":"Schizophr Bull"},{"key":"2077_CR25","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.neuron.2007.07.025","volume":"55","author":"JJ Palop","year":"2007","unstructured":"Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer\u2019s disease. Neuron. 2007;55:697\u2013711.","journal-title":"Neuron"},{"key":"2077_CR26","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1038\/s41380-022-01692-7","volume":"27","author":"L Pan","year":"2022","unstructured":"Pan L, Zheng L, Wu X, Zhu Z, Wang S, Lu Y, et al. A short period of early life oxytocin treatment rescues social behavior dysfunction via suppression of hippocampal hyperactivity in male mice. Mol Psychiatry. 2022;27:4157\u201371.","journal-title":"Mol Psychiatry"},{"key":"2077_CR27","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/s41380-024-02408-9","volume":"29","author":"E Spoleti","year":"2024","unstructured":"Spoleti E, La Barbera L, Cauzzi E, De Paolis ML, Saba L, Marino R, et al. Dopamine neuron degeneration in the Ventral Tegmental Area causes hippocampal hyperexcitability in experimental Alzheimer\u2019s Disease. Mol Psychiatry. 2024;29:1265\u201380.","journal-title":"Mol Psychiatry"},{"key":"2077_CR28","doi-asserted-by":"crossref","unstructured":"Yanagi M, Southcott S, Lister J, Tamminga CA. Animal Models of Schizophrenia. Progress in Molecular Biology and Translational Science, vol. 105, Elsevier; 2012. p. 411-44.","DOI":"10.1016\/B978-0-12-394596-9.00012-3"},{"key":"2077_CR29","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1176\/appi.ajp.157.7.1141","volume":"157","author":"XM Gao","year":"2000","unstructured":"Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry. 2000;157:1141\u20139.","journal-title":"Am J Psychiatry"},{"key":"2077_CR30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1176\/appi.ajp.2014.14010123","volume":"172","author":"W Li","year":"2015","unstructured":"Li W, Ghose S, Gleason K, Begovic A, Perez J, Bartko J, et al. Synaptic proteins in the hippocampus indicative of increased neuronal activity in CA3 in schizophrenia. AJP. 2015;172:373\u201382.","journal-title":"AJP"},{"key":"2077_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/mp.2014.54","volume":"20","author":"AD Stan","year":"2015","unstructured":"Stan AD, Ghose S, Zhao C, Hulsey K, Mihalakos P, Yanagi M, et al. Magnetic resonance spectroscopy and tissue protein concentrations together suggest lower glutamate signaling in dentate gyrus in schizophrenia. Mol Psychiatry. 2015;20:433\u20139.","journal-title":"Mol Psychiatry"},{"key":"2077_CR32","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1038\/s41380-020-0696-6","volume":"26","author":"JM Perez","year":"2021","unstructured":"Perez JM, Berto S, Gleason K, Ghose S, Tan C, Kim T-K, et al. Hippocampal subfield transcriptome analysis in schizophrenia psychosis. Mol Psychiatry. 2021;26:2577\u201389.","journal-title":"Mol Psychiatry"},{"key":"2077_CR33","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1126\/science.1140263","volume":"317","author":"TJ McHugh","year":"2007","unstructured":"McHugh TJ, Jones MW, Quinn JJ, Balthasar N, Coppari R, Elmquist JK, et al. Dentate gyrus NMDA receptors mediate rapid pattern separation in the hippocampal network. Science. 2007;317:94\u20139.","journal-title":"Science"},{"key":"2077_CR34","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1038\/s41380-018-0124-3","volume":"25","author":"A Segev","year":"2020","unstructured":"Segev A, Yanagi M, Scott D, Southcott SA, Lister JM, Tan C, et al. Reduced GluN1 in mouse dentate gyrus is associated with CA3 hyperactivity and psychosis-like behaviors. Mol Psychiatry. 2020;25:2832\u201343.","journal-title":"Mol Psychiatry"},{"key":"2077_CR35","doi-asserted-by":"publisher","unstructured":"Scott DS, Subramanian M, Yamamoto J, Tamminga CA. Schizophrenia pathology reverse-translated into mouse shows hippocampal hyperactivity, psychosis behaviors and hyper-synchronous events. Mol Psychiatry. 2024. https:\/\/doi.org\/10.1038\/s41380-024-02781-5.","DOI":"10.1038\/s41380-024-02781-5"},{"key":"2077_CR36","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.neuron.2016.01.040","volume":"89","author":"BL Roth","year":"2016","unstructured":"Roth BL. DREADDs for neuroscientists. Neuron. 2016;89:683\u201394.","journal-title":"Neuron"},{"key":"2077_CR37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S0006-3223(98)00138-3","volume":"44","author":"FM Benes","year":"1998","unstructured":"Benes FM, Kwok EW, Vincent SL, Todtenkopf MS. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol Psychiatry. 1998;44:88\u201397.","journal-title":"Biol Psychiatry"},{"key":"2077_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.schres.2007.05.033","volume":"95","author":"M-C Bertrand","year":"2007","unstructured":"Bertrand M-C, Sutton H, Achim AM, Malla AK, Lepage M. Social cognitive impairments in first episode psychosis. Schizophr Res. 2007;95:124\u201333.","journal-title":"Schizophr Res"},{"key":"2077_CR39","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1176\/appi.ajp.2012.12040490","volume":"170","author":"J Lee","year":"2013","unstructured":"Lee J, Altshuler L, Glahn DC, Miklowitz DJ, Ochsner K, Green MF. Social and nonsocial cognition in bipolar disorder and schizophrenia: relative levels of impairment. Am J Psychiatry. 2013;170:334\u201341.","journal-title":"Am J Psychiatry"},{"key":"2077_CR40","doi-asserted-by":"crossref","unstructured":"Tamminga E by CA, MD, Os J van, MD, PhD, MRCPsych et al., editors. Psychotic disorders: comprehensive conceptualization and treatments. Oxford, New York: Oxford University Press; 2020.","DOI":"10.1093\/med\/9780190653279.001.0001"},{"key":"2077_CR41","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1093\/schbul\/sbl029","volume":"32","author":"SM Couture","year":"2006","unstructured":"Couture SM, Penn DL, Roberts DL. The functional significance of social cognition in schizophrenia: a review. Schizophr Bull. 2006;32:S44\u201363.","journal-title":"Schizophr Bull"},{"key":"2077_CR42","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fnbeh.2019.00233","volume":"13","author":"N Tzakis","year":"2019","unstructured":"Tzakis N, Holahan MR. Social memory and the role of the hippocampal CA2 region. Front Behav Neurosci. 2019;13:233.","journal-title":"Front Behav Neurosci"},{"key":"2077_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.neures.2017.05.007","volume":"129","author":"T Okuyama","year":"2018","unstructured":"Okuyama T. Social memory engram in the hippocampus. Neurosci Res. 2018;129:17\u201323.","journal-title":"Neurosci Res"},{"key":"2077_CR44","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1126\/science.aaf7003","volume":"353","author":"T Okuyama","year":"2016","unstructured":"Okuyama T, Kitamura T, Roy DS, Itohara S, Tonegawa S. Ventral CA1 neurons store social memory. Science. 2016;353:1536\u201341.","journal-title":"Science"},{"key":"2077_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.conb.2020.12.008","volume":"68","author":"A Watarai","year":"2021","unstructured":"Watarai A, Tao K, Wang M-Y, Okuyama T. Distinct functions of ventral CA1 and dorsal CA2 in social memory. Curr Opin Neurobiol. 2021;68:29\u201335.","journal-title":"Curr Opin Neurobiol"},{"key":"2077_CR46","unstructured":"Davis C. Haloperidol. In: Enna SJ, Bylund DB, editors. xPharm: The Comprehensive Pharmacology Reference, New York: Elsevier; 2007. p. 1\u20137."},{"key":"2077_CR47","doi-asserted-by":"crossref","unstructured":"Janssen PAJ. The Evolution of The Butyrophenones, Haloperidol and Trifluperidol, From Meperidine-Like 4-Phenylpiperidines. In: Pfeiffer CC, Smythies JR, editors. International Review of Neurobiology, vol. 8, Academic Press; 1965. p. 221-63.","DOI":"10.1016\/S0074-7742(08)60759-X"},{"key":"2077_CR48","first-page":"10","volume":"3","author":"PA Janssen","year":"1967","unstructured":"Janssen PA. The pharmacology of haloperidol. Int J Neuropsychiatry. 1967;3:10\u201318.","journal-title":"Int J Neuropsychiatry"},{"key":"2077_CR49","doi-asserted-by":"crossref","unstructured":"Forsman A, \u00d6hman R. Pharmacokinetics and pharmacodynamics of haloperidol in man. In: Saletu B, Berner P, Hollister L, editors. Neuro-Psychopharmacology, Pergamon; 1979. p. 559-65.","DOI":"10.1016\/B978-0-08-023089-4.50064-8"},{"key":"2077_CR50","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1021\/acschemneuro.7b00018","volume":"8","author":"MW Tyler","year":"2017","unstructured":"Tyler MW, Zaldivar-Diez J, Haggarty SJ. Classics in chemical neuroscience: haloperidol. ACS Chem Neurosci. 2017;8:444\u201353.","journal-title":"ACS Chem Neurosci"},{"key":"2077_CR51","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.neuroscience.2017.07.068","volume":"361","author":"C L\u00e9vesque","year":"2017","unstructured":"L\u00e9vesque C, Hernandez G, Mahmoudi S, Calon F, Gasparini F, Gomez-Mancilla B, et al. Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs. Neuroscience. 2017;361:43\u201357.","journal-title":"Neuroscience"},{"key":"2077_CR52","unstructured":"Rahman S, Marwaha R Haloperidol. StatPearls, Treasure Island (FL): StatPearls Publishing; 2022."},{"key":"2077_CR53","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","volume":"54","author":"NC Bodick","year":"1997","unstructured":"Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997;54:465\u201373.","journal-title":"Arch Neurol"},{"key":"2077_CR54","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1527-3458.2003.tb00247.x","volume":"9","author":"NR Mirza","year":"2006","unstructured":"Mirza NR, Peters D, Sparks RG. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev. 2006;9:159\u201386.","journal-title":"CNS Drug Rev"},{"key":"2077_CR55","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.biopsych.2024.03.014","volume":"96","author":"SM Paul","year":"2024","unstructured":"Paul SM, Yohn SE, Brannan SK, Neugebauer NM, Breier A. Muscarinic receptor activators as novel treatments for schizophrenia. Biol Psychiatry. 2024;96:627\u201337.","journal-title":"Biol Psychiatry"},{"key":"2077_CR56","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa2017015","volume":"384","author":"SK Brannan","year":"2021","unstructured":"Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N. Engl J Med. 2021;384:717\u201326.","journal-title":"N. Engl J Med"},{"key":"2077_CR57","unstructured":"Commissioner O of the. FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia. FDA. 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-drug-new-mechanism-action-treatment-schizophrenia. Accessed 1 October 2024."},{"key":"2077_CR58","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1021\/acschemneuro.8b00625","volume":"10","author":"CA Thorn","year":"2019","unstructured":"Thorn CA, Moon J, Bourbonais CA, Harms J, Edgerton JR, Stark E, et al. Striatal, hippocampal, and cortical networks are differentially responsive to the M4- and M1-muscarinic acetylcholine receptor mediated effects of xanomeline. ACS Chem Neurosci. 2019;10:1753\u201364.","journal-title":"ACS Chem Neurosci"},{"key":"2077_CR59","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","volume":"42","author":"RA McCutcheon","year":"2019","unstructured":"McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci. 2019;42:205\u201320.","journal-title":"Trends Neurosci"},{"key":"2077_CR60","unstructured":"Correll CU, Angelov AS, Brannan SK. Safety and efficacy of KarXT (xanomeline-trospium) in patients with schizophrenia: results from a phase 3, randomised, double-blind, placebo-controlled trial (EMERGENT-2). Karuna Therapeutics. 2022. https:\/\/web.archive.org\/web\/20230104162608\/https:\/\/karunatx.com\/wpcontent\/uploads\/2022\/10\/ECNP-2022_Poster_EMERGENT-2_Correll_2022-10-16_FINAL_.pdf. Accessed 11 Apr 2024."},{"key":"2077_CR61","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","volume":"81","author":"I Kaul","year":"2024","unstructured":"Kaul I, Sawchak S, Walling DP, Tamminga CA, Breier A, Zhu H, et al. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2024;81:749\u201356.","journal-title":"JAMA Psychiatry"},{"key":"2077_CR62","first-page":"624","volume":"30","author":"A McKenna","year":"2024","unstructured":"McKenna A, Tice JA, Whittington MD, Wright AC, Richardson M, Raymond FR, et al. KarXT for schizophrenia\u2013effectiveness and value: a summary from the Institute for Clinical and Economic Review\u2019s New England Comparative Effectiveness Public Advisory Council. J Manag Care Spec Pharm. 2024;30:624\u20138.","journal-title":"J Manag Care Spec Pharm"},{"key":"2077_CR63","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","volume":"165","author":"A Shekhar","year":"2008","unstructured":"Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dub\u00e9 S, Mallinckrodt C, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. AJP. 2008;165:1033\u20139.","journal-title":"AJP"},{"key":"2077_CR64","doi-asserted-by":"publisher","first-page":"40913","DOI":"10.4088\/JCP.21m14316","volume":"83","author":"PJ Weiden","year":"2022","unstructured":"Weiden PJ, Breier A, Kavanagh S, Miller AC, Brannan SK, Paul SM. Antipsychotic efficacy of karXT (xanomeline\u2212trospium): post hoc analysis of positive and negative syndrome scale categorical response rates, time course of response, and symptom domains of response in a phase 2 study. J Clin Psychiatry. 2022;83:40913.","journal-title":"J Clin Psychiatry"},{"key":"2077_CR65","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.biopsych.2024.05.014","volume":"96","author":"OD Howes","year":"2024","unstructured":"Howes OD, Dawkins E, Lobo MC, Kaar SJ, Beck K. New drug treatments for schizophrenia: a review of approaches to target circuit dysfunction. Biol Psychiatry. 2024;96:638\u201350.","journal-title":"Biol Psychiatry"},{"key":"2077_CR66","unstructured":"Kumar A, Maini K, Kadian R. Levetiracetam. StatPearls, Treasure Island (FL): StatPearls Publishing; 2022."},{"key":"2077_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2023.114545","volume":"369","author":"AG Isla","year":"2023","unstructured":"Isla AG, Balleza-Tapia H, Chu F, Chen G, Johansson J, Nilsson P, et al. Low dose of levetiracetam counteracts amyloid \u03b2-induced alterations of hippocampal gamma oscillations by restoring fast-spiking interneuron activity. Exp Neurol. 2023;369:114545.","journal-title":"Exp Neurol"},{"key":"2077_CR68","doi-asserted-by":"publisher","first-page":"9861","DOI":"10.1073\/pnas.0308208101","volume":"101","author":"BA Lynch","year":"2004","unstructured":"Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci. 2004;101:9861\u20136.","journal-title":"Proc Natl Acad Sci"},{"key":"2077_CR69","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1152\/jn.00279.2011","volume":"106","author":"AL Meehan","year":"2011","unstructured":"Meehan AL, Yang X, McAdams BD, Yuan L, Rothman SM. A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam. J Neurophysiol. 2011;106:1227\u201339.","journal-title":"J Neurophysiol"},{"key":"2077_CR70","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.neulet.2008.02.076","volume":"436","author":"N Nagarkatti","year":"2008","unstructured":"Nagarkatti N, Deshpande LS, DeLorenzo RJ. Levetiracetam inhibits both ryanodine and IP3 receptor activated calcium induced calcium release in hippocampal neurons in culture. Neurosci Lett. 2008;436:289\u201393.","journal-title":"Neurosci Lett"},{"key":"2077_CR71","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1124\/jpet.113.208751","volume":"348","author":"M Wakita","year":"2014","unstructured":"Wakita M, Kotani N, Kogure K, Akaike N. Inhibition of excitatory synaptic transmission in hippocampal neurons by levetiracetam involves Zn2+-dependent GABA type a receptor\u2013mediated presynaptic modulation. J Pharm Exp Ther. 2014;348:246\u201359.","journal-title":"J Pharm Exp Ther"},{"key":"2077_CR72","first-page":"475","volume":"15","author":"IJ Contreras-Garc\u00eda","year":"2022","unstructured":"Contreras-Garc\u00eda IJ, C\u00e1rdenas-Rodr\u00edguez N, Romo-Mancillas A, Bandala C, Zamudio SR, G\u00f3mez-Manzo S, et al. Levetiracetam mechanisms of action: from molecules to systems. Pharm (Basel). 2022;15:475.","journal-title":"Pharm (Basel)"},{"key":"2077_CR73","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1528-1157.2002.24501.x","volume":"43","author":"EA Lukyanetz","year":"2002","unstructured":"Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002;43:9\u201318.","journal-title":"Epilepsia"},{"key":"2077_CR74","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.nicl.2015.02.009","volume":"7","author":"A Bakker","year":"2015","unstructured":"Bakker A, Albert MS, Krauss G, Speck CL, Gallagher M. Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance. Neuroimage Clin. 2015;7:688\u201398.","journal-title":"Neuroimage Clin"},{"key":"2077_CR75","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/YIC.0000000000000405","volume":"37","author":"F Behdani","year":"2022","unstructured":"Behdani F, Hassanzadeh B, Eslamzadeh M, Moradi M, Hebrani P, Dadgarmoghaddam M, et al. Can levetiracetam improve clinical symptoms in schizophrenic patients? A randomized placebo-controlled clinical trial. Int Clin Psychopharmacol. 2022;37:159.","journal-title":"Int Clin Psychopharmacol"},{"key":"2077_CR76","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41386-023-01730-0","volume":"49","author":"MJ Roeske","year":"2024","unstructured":"Roeske MJ, McHugo M, Rogers B, Armstrong K, Avery S, Donahue M, et al. Modulation of hippocampal activity in schizophrenia with levetiracetam: a randomized, double-blind, cross-over, placebo-controlled trial. Neuropsychopharmacology. 2024;49:681\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"2077_CR77","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1528-1167.2012.03603.x","volume":"54","author":"C Helmstaedter","year":"2013","unstructured":"Helmstaedter C, Mihov Y, Toliat MR, Thiele H, Nuernberg P, Schoch S, et al. Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam. Epilepsia. 2013;54:36\u201344.","journal-title":"Epilepsia"},{"key":"2077_CR78","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1212\/01.WNL.0000078031.32904.0D","volume":"61","author":"M Mula","year":"2003","unstructured":"Mula M, Trimble MR, Yuen A, Liu RSN, Sander JWAS. Psychiatric adverse events during levetiracetam therapy. Neurology. 2003;61:704\u20136.","journal-title":"Neurology"},{"key":"2077_CR79","volume":"2020","author":"O Ogunsakin","year":"2020","unstructured":"Ogunsakin O, Tumenta T, Louis-Jean S, Mahbub A, Rabel P, Olupona T, et al. Levetiracetam induced behavioral abnormalities in a patient with seizure disorder: a diagnostic challenge. Case Rep. Psychiatry. 2020;2020:8883802.","journal-title":"Case Rep. Psychiatry"},{"key":"2077_CR80","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.seizure.2022.12.002","volume":"116","author":"K Tao","year":"2024","unstructured":"Tao K, Chen H, Chen Y, Gu Y, Wang X. Levetiracetam induces severe psychiatric symptoms in people with epilepsy. Seizure: Eur J Epilepsy. 2024;116:147\u201350.","journal-title":"Seizure: Eur J Epilepsy"},{"key":"2077_CR81","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1021\/acsptsci.8b00012","volume":"1","author":"KJ Thompson","year":"2018","unstructured":"Thompson KJ, Khajehali E, Bradley SJ, Navarrete JS, Huang XP, Slocum S, et al. DREADD agonist 21 is an effective agonist for muscarinic-based DREADDs in vitro and in vivo. ACS Pharm Transl Sci. 2018;1:61\u201372.","journal-title":"ACS Pharm Transl Sci"},{"key":"2077_CR82","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1365-2826.2008.01734.x","volume":"20","author":"KJ Kov\u00e1cs","year":"2008","unstructured":"Kov\u00e1cs KJ. Measurement of immediate-early gene activation- c-fos and beyond. J Neuroendocrinol. 2008;20:665\u201372.","journal-title":"J Neuroendocrinol"},{"key":"2077_CR83","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/070674370004500302","volume":"45","author":"S Kapur","year":"2000","unstructured":"Kapur S, Wadenberg M-L, Remington G. Are animal studies of antipsychotics appropriately dosed?: lessons from the bedside to the bench. Can J Psychiatry. 2000;45:241\u20136.","journal-title":"Can J Psychiatry"},{"key":"2077_CR84","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.pbb.2008.11.016","volume":"92","author":"X-M Gao","year":"2009","unstructured":"Gao X-M, Elmer GI, Adams-Huet B, Tamminga CA. Social memory in mice: disruption with an NMDA antagonist and attenuation with antipsychotic drugs. Pharmacol Biochem Behav. 2009;92:236\u201342.","journal-title":"Pharmacol Biochem Behav"},{"key":"2077_CR85","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1037\/0735-7036.96.6.1000","volume":"96","author":"DH Thor","year":"1982","unstructured":"Thor DH, Holloway WR. Social memory of the male laboratory rat. J Comp Physiol Psychol. 1982;96:1000\u20136.","journal-title":"J Comp Physiol Psychol"},{"key":"2077_CR86","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0168-1591(99)00120-3","volume":"67","author":"OH Burman","year":"2000","unstructured":"Burman OH, Mendl M. Short-term social memory in the laboratory rat: its susceptibility to disturbance. Appl Anim Behav Sci. 2000;67:241\u201354.","journal-title":"Appl Anim Behav Sci"},{"key":"2077_CR87","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bbr.2018.01.019","volume":"354","author":"M-C Chiang","year":"2018","unstructured":"Chiang M-C, Huang AJY, Wintzer ME, Ohshima T, McHugh TJ. A role for CA3 in social recognition memory. Behav Brain Res. 2018;354:22\u201330.","journal-title":"Behav Brain Res"},{"key":"2077_CR88","unstructured":"Lemaire M. Social recognition task in the rat. Curr Protoc Pharmacol. 2003;Chapter 5:Unit5.30."},{"key":"2077_CR89","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/sj.npp.1300151","volume":"28","author":"MB Andersen","year":"2003","unstructured":"Andersen MB, Fink-Jensen A, Peacock L, Gerlach J, Bymaster F, Lundbaek JA, et al. The muscarinic M1\/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology. 2003;28:1168\u201375.","journal-title":"Neuropsychopharmacology"},{"key":"2077_CR90","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.1523\/JNEUROSCI.0370-11.2011","volume":"31","author":"D Dencker","year":"2011","unstructured":"Dencker D, W\u00f6rtwein G, Weikop P, Jeon J, Thomsen M, Sager TN, et al. Involvement of a subpopulation of neuronal m4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1\/M4 preferring muscarinic receptor agonist xanomeline. J Neurosci. 2011;31:5905\u20138.","journal-title":"J Neurosci"},{"key":"2077_CR91","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1146\/annurev-pharmtox-051921-023858","volume":"64","author":"EJ Nunes","year":"2024","unstructured":"Nunes EJ, Addy NA, Conn PJ, Foster DJ. Targeting the actions of muscarinic receptors on dopamine systems: new strategies for treating neuropsychiatric disorders. Annu Rev Pharmacol Toxicol. 2024;64:277\u201389.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2077_CR92","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S0022-3565(24)34979-1","volume":"290","author":"HE Shannon","year":"1999","unstructured":"Shannon HE, Hart JC, Bymaster FP, Calligaro DO, DeLapp NW, Mitch CH, et al. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. J Pharm Exp Ther. 1999;290:901\u20137.","journal-title":"J Pharm Exp Ther"},{"key":"2077_CR93","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0920-9964(99)00138-3","volume":"42","author":"HE Shannon","year":"2000","unstructured":"Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MD, et al. Xanomeline, an M(1)\/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res. 2000;42:249\u201359.","journal-title":"Schizophr Res"},{"key":"2077_CR94","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.yebeh.2008.07.012","volume":"13","author":"C Helmstaedter","year":"2008","unstructured":"Helmstaedter C, Witt J-A. The effects of levetiracetam on cognition: a non-interventional surveillance study. Epilepsy Behav. 2008;13:642\u20139.","journal-title":"Epilepsy Behav"},{"key":"2077_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40263-023-01058-9","volume":"38","author":"C-Y Lin","year":"2024","unstructured":"Lin C-Y, Chang M-C, Jhou H-J. Effect of levetiracetam on cognition: a systematic review and meta-analysis of double-blind randomized placebo-controlled trials. CNS Drugs. 2024;38:1\u201314.","journal-title":"CNS Drugs"},{"key":"2077_CR96","doi-asserted-by":"publisher","first-page":"E2895","DOI":"10.1073\/pnas.1121081109","volume":"109","author":"PE Sanchez","year":"2012","unstructured":"Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer\u2019s disease model. Proc Natl Acad Sci USA. 2012;109:E2895\u20132903.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2077_CR97","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.schres.2017.06.027","volume":"193","author":"MT Koh","year":"2018","unstructured":"Koh MT, Shao Y, Rosenzweig-Lipson S, Gallagher M. Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia. Schizophr Res. 2018;193:119\u201325.","journal-title":"Schizophr Res"},{"key":"2077_CR98","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1007\/s13311-017-0541-z","volume":"14","author":"RP Haberman","year":"2017","unstructured":"Haberman RP, Branch A, Gallagher M. Targeting neural hyperactivity as a treatment to stem progression of late-onset Alzheimer\u2019s disease. Neurotherapeutics. 2017;14:662\u201376.","journal-title":"Neurotherapeutics"},{"key":"2077_CR99","first-page":"37","volume":"60","author":"CW Huang","year":"2009","unstructured":"Huang CW, Tsai JJ, Huang CC, Wu SN. Experimental and simulation studies on the mechanisms of levetiracetam-mediated inhibition of delayed-rectifier potassium current (KV3.1): contribution to the firing of action potentials. J Physiol Pharm. 2009;60:37\u201347.","journal-title":"J Physiol Pharm"},{"key":"2077_CR100","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.nlm.2013.02.001","volume":"102","author":"L Devi","year":"2013","unstructured":"Devi L, Ohno M. Effects of levetiracetam, an antiepileptic drug, on memory impairments associated with aging and Alzheimer\u2019s disease in mice. Neurobiol Learn Mem. 2013;102:7\u201311.","journal-title":"Neurobiol Learn Mem"},{"key":"2077_CR101","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/npp.2013.30","volume":"38","author":"JE Robinson","year":"2013","unstructured":"Robinson JE, Chen M, Stamatakis AM, Krouse MC, Howard EC, Faccidomo S, et al. Levetiracetam has opposite effects on alcohol- and cocaine-related behaviors in C57BL\/6J mice. Neuropsychopharmacology. 2013;38:1322\u201333.","journal-title":"Neuropsychopharmacology"},{"key":"2077_CR102","first-page":"517","volume":"11","author":"OME Abdel-Salam","year":"2012","unstructured":"Abdel-Salam OME, El-Sayed El-Shamarka M, Salem NA, El-Mosallamy AEMK, Sleem AA. Amelioration of the haloperidol-induced memory impairment and brain oxidative stress by cinnarizine. EXCLI J. 2012;11:517\u201330.","journal-title":"EXCLI J"},{"key":"2077_CR103","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/026988110001400206","volume":"14","author":"E Legangneux","year":"2000","unstructured":"Legangneux E, McEwen J, Wesnes KA, Bergougnan L, Miget N, Canal M, et al. The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers. J Psychopharmacol. 2000;14:164\u201371.","journal-title":"J Psychopharmacol"},{"key":"2077_CR104","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.bandc.2004.09.005","volume":"58","author":"C Lustig","year":"2005","unstructured":"Lustig C, Meck WH. Chronic treatment with haloperidol induces deficits in working memory and feedback effects of interval timing. Brain Cogn. 2005;58:9\u201316.","journal-title":"Brain Cogn"},{"key":"2077_CR105","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.pharep.2015.01.017","volume":"67","author":"M Krzystanek","year":"2015","unstructured":"Krzystanek M, Bogus K, Pa\u0142asz A, Krzystanek E, Worthington JJ, Wiaderkiewicz R. Effects of long-term treatment with the neuroleptics haloperidol, clozapine and olanzapine on immunoexpression of NMDA receptor subunits NR1, NR2A and NR2B in the rat hippocampus. Pharmacol Rep. 2015;67:965\u20139.","journal-title":"Pharmacol Rep."},{"key":"2077_CR106","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.3390\/ijms20061442","volume":"20","author":"M Krzystanek","year":"2019","unstructured":"Krzystanek M, Pa\u0142asz A. NMDA receptor model of antipsychotic drug-induced hypofrontality. Int J Mol Sci. 2019;20:1442.","journal-title":"Int J Mol Sci"},{"key":"2077_CR107","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/sj.npp.1301356","volume":"32","author":"X L\u00f3pez-Gil","year":"2007","unstructured":"L\u00f3pez-Gil X, Babot Z, Amarg\u00f3s-Bosch M, Su\u00f1ol C, Artigas F, Adell A. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacol. 2007;32:2087\u201397.","journal-title":"Neuropsychopharmacol"},{"key":"2077_CR108","doi-asserted-by":"publisher","first-page":"1808361","DOI":"10.1080\/19932820.2020.1808361","volume":"15","author":"H Ueno","year":"2020","unstructured":"Ueno H, Suemitsu S, Murakami S, Kitamura N, Wani K, Takahashi Y, et al. Effects of haloperidol inhalation on MK-801- and memantine-induced locomotion in mice. Libyan J Med. 2020;15:1808361.","journal-title":"Libyan J Med"},{"key":"2077_CR109","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/026988119400800402","volume":"8","author":"SL Eastwood","year":"1994","unstructured":"Eastwood SL, Story P, Burnet PWJ, Heath P, Harrison PJ. Differential changes in glutamate receptor subunit messenger RNAs in rat brain after haloperidol treatment. J Psychopharmacol. 1994;8:196\u2013203.","journal-title":"J Psychopharmacol"},{"key":"2077_CR110","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0304-3940(96)12801-9","volume":"212","author":"SL Eastwood","year":"1996","unstructured":"Eastwood SL, Porter RH, Harrison PJ. The effect of chronic haloperidol treatment on glutamate receptor subunit (GluR1, GluR2, KA1, KA2, NR1) mRNAs and glutamate binding protein mRNA in rat forebrain. Neurosci Lett. 1996;212:163\u20136.","journal-title":"Neurosci Lett"},{"key":"2077_CR111","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/npp.2015.189","volume":"41","author":"A Ghoshal","year":"2016","unstructured":"Ghoshal A, Rook JM, Dickerson JW, Roop GN, Morrison RD, Jalan-Sakrikar N, et al. Potentiation of M1 muscarinic receptor reverses plasticity deficits and negative and cognitive symptoms in a schizophrenia mouse model. Neuropsychopharmacol. 2016;41:598\u2013610.","journal-title":"Neuropsychopharmacol"},{"key":"2077_CR112","doi-asserted-by":"publisher","DOI":"10.1186\/1756-6606-5-10","volume":"5","author":"H Koshimizu","year":"2012","unstructured":"Koshimizu H, Leiter LM, Miyakawa T. M4 muscarinic receptor knockout mice display abnormal social behavior and decreased prepulse inhibition. Mol Brain. 2012;5:10.","journal-title":"Mol Brain"},{"key":"2077_CR113","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neuroscience.2019.07.003","volume":"414","author":"T Mandai","year":"2019","unstructured":"Mandai T, Kasahara M, Kurimoto E, Tanaka M, Suzuki M, Nakatani A, et al. In vivo pharmacological comparison of TAK-071, a positive allosteric modulator of muscarinic M1 receptor, and xanomeline, an agonist of muscarinic M1\/M4 receptor, in rodents. Neuroscience. 2019;414:60\u201376.","journal-title":"Neuroscience"},{"key":"2077_CR114","doi-asserted-by":"publisher","first-page":"106344","DOI":"10.1016\/j.yebeh.2019.05.039","volume":"100","author":"FME Pinckaers","year":"2019","unstructured":"Pinckaers FME, Boon ME, Majoie MHJM. Risk factors predisposing to psychotic symptoms during levetiracetam therapy: A retrospective study. Epilepsy Behav. 2019;100:106344.","journal-title":"Epilepsy Behav"},{"key":"2077_CR115","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jamaneurol.2022.1269","volume":"79","author":"M-H Bj\u00f8rk","year":"2022","unstructured":"Bj\u00f8rk M-H, Zoega H, Leinonen MK, Cohen JM, Dreier JW, Furu K, et al. Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability. JAMA Neurol. 2022;79:672\u201381.","journal-title":"JAMA Neurol"},{"key":"2077_CR116","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209821","volume":"103","author":"SN Barnard","year":"2024","unstructured":"Barnard SN, Chen Z, Kanner AM, Holmes MG, Klein P, Abou-Khalil BW, et al. The adverse effects of commonly prescribed antiseizure medications in adults with newly diagnosed focal epilepsy. Neurology. 2024;103:e209821.","journal-title":"Neurology"},{"key":"2077_CR117","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/schbul\/sbac106","volume":"49","author":"AM Cavichioli","year":"2023","unstructured":"Cavichioli AM, Santos-Silva T, Grace AA, Guimar\u00e3es FS, Gomes FV. Levetiracetam attenuates adolescent stress-induced behavioral and electrophysiological changes associated with schizophrenia in adult rats. Schizophrenia Bull. 2023;49:68\u201377.","journal-title":"Schizophrenia Bull"},{"key":"2077_CR118","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/mp.2013.49","volume":"19","author":"M Yanagi","year":"2014","unstructured":"Yanagi M, Joho RH, Southcott SA, Shukla AA, Ghose S, Tamminga CA. Kv3.1-containing K(+) channels are reduced in untreated schizophrenia and normalized with antipsychotic drugs. Mol Psychiatry. 2014;19:573\u20139.","journal-title":"Mol Psychiatry"},{"key":"2077_CR119","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/nature08002","volume":"459","author":"JA Cardin","year":"2009","unstructured":"Cardin JA, Carl\u00e9n M, Meletis K, Knoblich U, Zhang F, Deisseroth K, et al. Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature. 2009;459:663\u20137.","journal-title":"Nature"},{"key":"2077_CR120","doi-asserted-by":"publisher","unstructured":"Iturra-Mena AM, Aguilar-Rivera M, Arriagada-Solimano M, P\u00e9rez-Valenzuela C, Fuentealba P, Dagnino-Subiabre A. Impact of stress on gamma oscillations in the rat nucleus accumbens during spontaneous social interaction. Front Behav Neurosci. 2019;13. https:\/\/doi.org\/10.3389\/fnbeh.2019.00151.","DOI":"10.3389\/fnbeh.2019.00151"},{"key":"2077_CR121","doi-asserted-by":"publisher","unstructured":"Guan A, Wang S, Huang A, Qiu C, Li Y, Li X, et al. The role of gamma oscillations in central nervous system diseases: Mechanism and treatment. Front Cell Neurosci. 2022;16. https:\/\/doi.org\/10.3389\/fncel.2022.962957.","DOI":"10.3389\/fncel.2022.962957"},{"key":"2077_CR122","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay4073","volume":"6","author":"L Liu","year":"2020","unstructured":"Liu L, Xu H, Wang J, Li J, Tian Y, Zheng J, et al. Cell type\u2013differential modulation of prefrontal cortical GABAergic interneurons on low gamma rhythm and social interaction. Sci Adv. 2020;6:eaay4073.","journal-title":"Sci Adv"},{"key":"2077_CR123","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.neuroscience.2022.04.020","volume":"493","author":"SR John","year":"2022","unstructured":"John SR, Dagash W, Mohapatra AN, Netser S, Wagner S. Distinct dynamics of theta and gamma rhythmicity during social interaction suggest differential mode of action in the medial amygdala of Sprague Dawley rats and C57BL\/6J mice. Neuroscience. 2022;493:69\u201380.","journal-title":"Neuroscience"},{"key":"2077_CR124","doi-asserted-by":"publisher","unstructured":"Zwierzy\u0144ska E, Pietrzak B. The differential effect of levetiracetam on memory and anxiety in rats. Epilepsy Behav. 2022;136. https:\/\/doi.org\/10.1016\/j.yebeh.2022.108917.","DOI":"10.1016\/j.yebeh.2022.108917"},{"key":"2077_CR125","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/hipo.20808","volume":"21","author":"MA Yassa","year":"2011","unstructured":"Yassa MA, Lacy JW, Stark SM, Albert MS, Gallagher M, Stark CEL. Pattern separation deficits associated with increased hippocampal CA3 and dentate gyrus activity in nondemented older adults. Hippocampus. 2011;21:968\u201379.","journal-title":"Hippocampus"},{"key":"2077_CR126","doi-asserted-by":"publisher","first-page":"7569","DOI":"10.1523\/JNEUROSCI.0518-16.2016","volume":"36","author":"D Berron","year":"2016","unstructured":"Berron D, Schutze H, Maass A, Cardenas-Blanco A, Kuijf HJ, Kumaran D, et al. Strong evidence for pattern separation in human dentate gyrus. J Neurosci. 2016;36:7569\u201379.","journal-title":"J Neurosci"},{"key":"2077_CR127","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.schres.2014.05.006","volume":"159","author":"T Das","year":"2014","unstructured":"Das T, Ivleva EI, Wagner AD, Stark CEL, Tamminga CA. Loss of pattern separation performance in schizophrenia suggests dentate gyrus dysfunction. Schizophr Res. 2014;159:193\u20137.","journal-title":"Schizophr Res"},{"key":"2077_CR128","doi-asserted-by":"publisher","first-page":"9570","DOI":"10.1523\/JNEUROSCI.0940-19.2019","volume":"39","author":"D GoodSmith","year":"2019","unstructured":"GoodSmith D, Lee H, Neunuebel JP, Song H, Knierim JJ. Dentate gyrus mossy cells share a role in pattern separation with dentate granule cells and proximal CA3 pyramidal cells. J Neurosci. 2019;39:9570\u201384.","journal-title":"J Neurosci"},{"key":"2077_CR129","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.tins.2011.06.006","volume":"34","author":"MA Yassa","year":"2011","unstructured":"Yassa MA, Stark CEL. Pattern separation in the hippocampus. Trends Neurosci. 2011;34:515\u201325.","journal-title":"Trends Neurosci"},{"key":"2077_CR130","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.nlm.2015.07.008","volume":"129","author":"ET Rolls","year":"2016","unstructured":"Rolls ET. Pattern separation, completion, and categorisation in the hippocampus and neocortex. Neurobiol Learn Mem. 2016;129:4\u201328.","journal-title":"Neurobiol Learn Mem"},{"key":"2077_CR131","doi-asserted-by":"publisher","first-page":"6018","DOI":"10.1021\/acs.jmedchem.5b00624","volume":"58","author":"I Sola","year":"2015","unstructured":"Sola I, Aso E, Frattini D, L\u00f3pez-Gonz\u00e1lez I, Espargar\u00f3 A, Sabat\u00e9 R, et al. Novel levetiracetam derivatives that are effective against the alzheimer-like phenotype in mice: synthesis, in vitro, ex vivo, and in vivo efficacy studies. J Med Chem. 2015;58:6018\u201332.","journal-title":"J Med Chem"},{"key":"2077_CR132","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1111\/cns.12144","volume":"19","author":"J-Q Shi","year":"2013","unstructured":"Shi J-Q, Wang B-R, Tian Y-Y, Xu J, Gao L, Zhao S-L, et al. Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APPswe\/PS1dE9 transgenic mice. CNS Neurosci Therapeutics. 2013;19:871\u201381.","journal-title":"CNS Neurosci Therapeutics"},{"key":"2077_CR133","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jamaneurol.2021.3310","volume":"78","author":"K Vossel","year":"2021","unstructured":"Vossel K, Ranasinghe KG, Beagle AJ, La A, Ah Pook K, Castro M, et al. Effect of levetiracetam on cognition in patients with alzheimer disease with and without epileptiform activity: a randomized clinical trial. JAMA Neurol. 2021;78:1345\u201354.","journal-title":"JAMA Neurol"},{"key":"2077_CR134","doi-asserted-by":"publisher","DOI":"10.1002\/alz.045476","volume":"16","author":"CS Musaeus","year":"2020","unstructured":"Musaeus CS, Zhao L, Dai W, Breton J, Shafi M, Alsop DC, et al. A randomized controlled trial measuring changes in cerebral blood flow after levetiracetam in patients with Alzheimer\u2019s disease. Alzheimer\u2019s Dement 2020;16:e045476.","journal-title":"Alzheimer\u2019s Dement"},{"key":"2077_CR135","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3233\/JAD-160742","volume":"58","author":"CS Musaeus","year":"2017","unstructured":"Musaeus CS, Shafi MM, Santarnecchi E, Herman ST, Press DZ. Levetiracetam alters oscillatory connectivity in Alzheimer\u2019s disease. J Alzheimer\u2019s Dis. 2017;58:1065\u201376.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"2077_CR136","doi-asserted-by":"crossref","unstructured":"Tamminga CA, Ivleva EI, van Reininghaus U, Os J editors. Psychotic disorders: comprehensive conceptualization and treatments. New York, NY: Oxford University Press; 2021.","DOI":"10.1093\/med\/9780190653279.001.0001"},{"key":"2077_CR137","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.schres.2005.02.007","volume":"79","author":"MR Broome","year":"2005","unstructured":"Broome MR, Woolley JB, Tabraham P, Johns LC, Bramon E, Murray GK, et al. What causes the onset of psychosis? Schizophrenia Res. 2005;79:23\u201334.","journal-title":"Schizophrenia Res"},{"key":"2077_CR138","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/wps.20490","volume":"17","author":"J Radua","year":"2018","unstructured":"Radua J, Ramella-Cravaro V, Ioannidis JPA, Reichenberg A, Phiphopthatsanee N, Amir T, et al. What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry. 2018;17:49\u201366.","journal-title":"World Psychiatry"},{"key":"2077_CR139","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1017\/S1352465808004955","volume":"37","author":"R Dudley","year":"2009","unstructured":"Dudley R, Siitarinen J, James I, Dodgson G. What do people with psychosis think caused their psychosis? A Q methodology study. Behav Cogn Psychother. 2009;37:11\u201324.","journal-title":"Behav Cogn Psychother"},{"key":"2077_CR140","first-page":"35","volume":"33","author":"PV Gejman","year":"2010","unstructured":"Gejman PV, Sanders AR, Duan J. The role of genetics in the etiology of schizophrenia. Psychiatr Clin. 2010;33:35\u201366.","journal-title":"Psychiatr Clin"},{"key":"2077_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.05.009","volume":"163","author":"SF Sonnenschein","year":"2020","unstructured":"Sonnenschein SF, Grace AA. Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia. Neuropharmacology. 2020;163:107632.","journal-title":"Neuropharmacology"},{"key":"2077_CR142","first-page":"4447","volume":"27","author":"S McGarrity","year":"2017","unstructured":"McGarrity S, Mason R, Fone KC, Pezze M, Bast T. Hippocampal neural disinhibition causes attentional and memory deficits. Cereb Cortex. 2017;27:4447\u201362.","journal-title":"Cereb Cortex"},{"key":"2077_CR143","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/npp.2013.305","volume":"39","author":"JA Hadley","year":"2014","unstructured":"Hadley JA, Nenert R, Kraguljac NV, Bolding MS, White DM, Skidmore FM, et al. Ventral tegmental area\/midbrain functional connectivity and response to antipsychotic medication in schizophrenia. Neuropsychopharmacology. 2014;39:1020\u201330.","journal-title":"Neuropsychopharmacology"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02077-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02077-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02077-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T13:02:28Z","timestamp":1750078948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02077-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":143,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2077"],"URL":"https:\/\/doi.org\/10.1038\/s41386-025-02077-4","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"type":"print","value":"0893-133X"},{"type":"electronic","value":"1740-634X"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Currently, CAT is a founding member of Neuventis, Stockholm, Sweden; she held Karuna stock during the development of Cobenfy; is a member of DSBM at Merck; and is a part-time advisor of Kynexis. DSS and FPD declare no potential competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}